Nebulized medications for the treatment of dyspnea: A literature review

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 1, 2015, Pages 1-19

  Boyden, Jackelyn Y ^a   Connor, Stephen R ^a   Otolorin, Lily ^a   Nathan, Steven D ^b   Fine, Perry G ^c   Davis, Malene S ^a   Muir, J Cameron ^a  

^a Capital Caring   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

advanced lung disease; dyspnea; nebulized medications; nebulized therapies

Indexed keywords

FENTANYL; FUROSEMIDE; HYDROMORPHONE; MORPHINE; OPIATE DERIVATIVE; AEROSOL; LOOP DIURETIC AGENT; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG DELIVERY DEVICE; DRUG SAFETY; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; NEBULIZATION; NEBULIZER; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; AEROSOL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AEROSOLS; ANALGESICS, OPIOID; DYSPNEA; FUROSEMIDE; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 84922529381     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1136     Document Type: Article

References (93)

1. Dudgeon D, and Shadd J: Assessment and management of dyspnea in palliative care. 2012. Available at www.uptodate.com/contents/assessment-and-management-of-dyspnea-in- palliative-care. Accessed January 31, 2014.
2. Solano JP, Gomes B, and Higginson IJ: A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31:58-69.
3. Currow DC, Plummer JL, Crockett A, and Abernethy AP: A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage. 2009;38: 533-545.
4. Moody LE, and McMillan S: Dyspnea and quality of life indicators in hospice patients and their caregivers. Health Qual Life Outcomes. 2003;1:9.
5. Blinderman CD, Homel P, Billings JA, Tennstedt S, and Portenoy RK: Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009;38:115-123.
6. Edmonds P, Higginson I, Altmann D, Sen-Gupta G, and McDonnell M: Is the presence of dyspnea a risk factor for morbidity in cancer patients? J Pain Symptom Manage. 2000;19:15-22.
7. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, Mahler DA, Meek PM, O'Donnell DE; American Thoracic Society Committee on Dyspnea: An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435-452.
8. Clemens KE, and Klaschik E: Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Support Care Cancer. 2008;16:93-99.
9. LeGrand SB, Khawam EA, Walsh D, and Rivera NI: Opioids, respiratory function, and dyspnea. Am J Hosp Palliat Care. 2003;20:57-61.
10. Rocker G, Horton R, Currow D, Goodridge D, Young J, and Booth S: Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009;64:910-915.
11. Booth S, Bausewein C, Higginson I, and Moosavi SH: Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med. 2009;3:21-36.
12. Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, and Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29:613-618.
13. Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y, and Mishima M: Continuous morphine infusion for endstage lung cancer patients. Oncol Lett. 2013;5:972-974.
14. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, and Bui C: Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327: 523-528.
15. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ, and Abernethy AP: Oncedaily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42:388-399.
16. Gauna AA, Kang SK, Triano ML, Swatko ER, and Vanston VJ: Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. J Palliat Med. 2008;11:643-648.
17. Kawabata M, and Kaneishi K: Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study. Am J Hosp Palliat Care. 2013;30:305-311.
18. Dessanges JF: A history of nebulization. J Aerosol Med. 2001;14:65-71.
19. Chandler S: Nebulized opioids to treat dyspnea. Am J Hosp Palliat Care. 1999;16:418-422.
20. Kallet RH: The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007;52:900-910.
21. Owens D: Nebulized furosemide for the treatment of dyspnea. J Hosp Palliat Nurs. 1999;16:418-422.
22. Zebraski SE, Kochenash SM, and Raffa RB: Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66:2221-2231.
23. DiSalvo WM, Joyce MM, Tyson LB, Culkin AE, and Mackay K: Putting evidence into practice: evidence-based interventions for cancer-related dyspnea. Clin J Oncol Nurs. 2008;12:341-352.
24. Foral PA, Malesker MA, Huerta G, and Hilleman DE: Nebulized opioids use in COPD. Chest. 2004;125:691-694.
25. Ripamonti C: Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999;7:233-243.
26. Joyce M, McSweeney M, Carrieri-Kohlman VL, and Hawkins J: The use of nebulized opioids in the management of dyspnea: evidence synthesis. Oncol Nurs Forum. 2004;31:551-561.
27. Newton PJ, Davidson PM, Macdonald P, Ollerton R, and Krum H: Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage. 2008;36:424-441.
28. Jeba J, George R, and Pease N: Nebulised furosemide in the palliation of dysponea in cancer: a systematic review. BMJ Support Palliat Care. 2013. [Epub ahead of print]
29. Chan K, Sham M, Tse D, and Thorsen A: Palliative medicine in malignant respiratory diseases. In: The Oxford Textbook of Palliative Medicine, 3rd ed. Oxford University Press, New York, NY; 2005.
30. Fine P: The Hospice Companion, 2nd ed. Oxford University Press, New York, NY; 2012.
31. Currow DC, Abernethy AP, and Ko DN: The active identification and management of chronic refractory breathlessness is a human right. Thorax. 2014;69:393-394.
32. Caffrey C, Sengupta M, Moss A, Harris-Kojetin L, and Valverde R: Home health care and discharged hospice care patients: United States, 2000 and 2007. Natl Health Stat Report. 2011;38:1-27.
33. Cronin P, Ryan F, and Coughlan M: Undertaking a literature review: a step-by-step approach. Br J Nurs. 2008;17:38-43.
34. Marrelli A: The performance technologist's toolbox: literature reviews. Perform Improv. 2005;44(7):40-44.
35. Ong K-C, Kor A-C, Chong W-F, Earnest A, and Wang Y-T: Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1028-1033.
36. Higgins JPT, and Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. In: JPT Higgins, (ed). The Cochrane Collaboration. March 2011. Available at: www.cochrane-handbook.org. Accessed January 31, 2014.
37. Williams CM: Dyspnea. Cancer J. 2006;12:365-373.
38. Dudgeon D: Dyspnea, death rattle, and cough. In: BR Ferrell, and N Coyle, (eds). Oxford Textbook of Palliative Nursing, 3rd ed. Oxford University Press, New York, NY; pp. 169-170, 2010.
39. Stone P, Rix, Kurowska A, and Tookman: Re: nebulized furosemide for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002;24:274-275; author reply 275- 276.
40. Davis C, Penn K, A'Hern R, Daniels J, and Slevin M: Single-dose randomized, controlled trial of nebulized morphine in patients with cancer-related breathlessness. Palliat Med. 1996;10:64-65.
41. Peterson G, Young R, Dunne P, Galloway J, and Parks T: Pilot study of nebulized morphine for dyspnoea in palliative care patients. Aust J Hosp Pharm. 1996;26:545-547.
42. Tanaka K, Shima Y, Kakinuma R, Kubota K, Ohe Y, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Nagai K, and Nishiwaki Y: Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clin Oncol. 1999;29:600-603.
43. Zeppetella G: Nebulized morphine in the palliation of dyspnoea. Palliat Med. 1997;11:267-275.
44. Quigley C, Joel S, Patel N, Baksh A, and Slevin M: A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness. J Pain Symptom Manage. 2002;23:7-9.
45. Wilcock A, Walton A, Manderson C, Feathers L, El Khoury B, Lewis M, Chauhan A, Howard P, Bell S, Frisby J, and Tattersfield A: Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax. 2008;63:872-875.
46. Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, Shima Y, and Uchitomi Y: Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage. 2003;26:962-967.
47. Shimoyama N, and Shimoyama M: Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002;23:73-76.
48. Sarhill N, Walsh D, Khawam E, Tropiano P, and Stahley MK: Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000;17: 389-391.
49. Charles MA, Reymond L, and Israel F: Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008;36:29-38.
50. Coyne PJ, Viswanathan R, and Smith TJ: Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage. 2002;23:157-160.
51. Quelch PC, Faulkner DE, and Yun JW: Nebulized opioids in the treatment of dyspnea. J Palliat Care. 1997;13:48-52.
52. Jensen D, Amjadi K, Harris-McAllister V, Webb KA, and O'Donnell DE: Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax. 2008;63:606-613.
53. Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, and O'Donnell DE: Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012;43:706-719.
54. Farncombe M, Chater S, and Gillin A: The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994;8:306-312.
55. Young IH, Daviskas E, and Keena VA: Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989;44:387-390.
56. Sheikh Motahar Vahedi H, Mahshidfar B, Rabiee H, Saadat S, Shokoohi H, Chardoli M, and Rahimi-Movaghar V: The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial. Respir Care. 2013;58:1873-1877.
57. Beauford W, Saylor TT, Stansbury DW, Avalos K, and Light RW: Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest. 1993;104:175-178.
58. Jankelson D, Hosseini K, Mather LE, Seale JP, and Young IH: Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2270-2274.
59. Leung R, Hill P, and Burdon J: Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996;51:596-600.
60. Masood AR, Reed JW, and Thomas SH: Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995;50: 629-634.
61. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, and de Maertelaer V: Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997;10:1079-1083.
62. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, and Marciniuk DD: Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995;152(6 Pt 1):1940-1945.
63. Cohen SP, and Dawson TC: Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics. 2002;110:e38.
64. Graff GR, Stark JM, and Grueber R: Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration. 2004;71:646-649.
65. Hayes D Jr, Anstead MI, Warner RT, Kuhn RJ, and Ballard HO: Inhaled morphine for palliation of dyspnea in endstage cystic fibrosis. Am J Health Syst Pharm. 2010;67:737-740.
66. Janahi IA, Maciejewski SR, Teran JM, and Oermann CM: Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatr Pulmonol. 2000;30:257-259.
67. 2 ventilatory responsiveness in humans. Pulm Pharmacol Ther. 2002;15:363-368.
68. Moosavi SH, Binks AP, Lansing RW, Topulos GP, Banzett RB, and Schwartzstein RM: Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156:1-8.
69. Nishino T, Ide T, Sudo T, and Sato J: Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med. 2000;161:1963-1967.
70. Laveneziana P, Galarducci A, Binazzi B, Stendardi L, Duranti R, and Scano G: Inhaled furosemide does not alleviate respiratory effort during flow-limited exercise in healthy subjects. Pulm Pharmacol Ther. 2008;21: 196-200.
71. Farncombe M, and Chater S: Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage. 1993;8:221-225.
72. Farncombe M, and Chater S: Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer. 1994;2:184-187.
73. Polosa R, Simidchiev A, and Walters EH: Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev. 2002;(3):CD002872.
74. Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, and Bausewein C: Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012;15:1374-1381.
75. Baydur A: Nebulized morphine: a convenient and safe alternative to dyspnea relief? Chest. 2004;125:363-365.
76. Ahmedzai S, and Davis C: Nebulised drugs in palliative care. Thorax. 1997;52 Suppl 2:S75-S77.
77. Finlay WH, and Martin AR: Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv. 2008;21:189-206.
78. Smaldone GC: Drug delivery via aerosol systems: concept of ''aerosol inhaled.'' J Aerosol Med. 1991;4:229-235.
79. Westphal CG, and Campbell ML: Nebulized morphine for terminal dyspnea. Am J Nurs. 2002;Suppl:11-15.
80. Campion J, and Snyder L: Palliative care of dyspnea in patients with advanced COPD. Elder Care, March 2011.
81. Doorley J, Hobbs M, Delaney E, and Murphy J: The role of nebulized opioids in managing terminal dyspnea: implications for the clinical nurse specialist. Clin Nurse Spec. 2003;17:19-21.
82. Ferraresi V: Inhaled opioids for the treatment of dyspnea. Am J Health Syst Pharm. 2005;62:319-320.
83. Jennings AL, Davies AN, Higgins JP, and Broadley K: Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. 2001;(4):CD002066.
84. Murray A, and Hagen NA: Hydromorphone. J Pain Symptom Manage. 2005;29(5 Suppl):S57-S66.
85. Kamal AH, Maguire JM, Wheeler JL, Currow DC, and Abernethy AP: Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med. 2012;15:106-114.
86. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, and Smith A: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23:249-260.
87. Steckel H, and Eskandar F: Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci. 2003;19:443-455.
88. McCallion ON, Taylor KM, Thomas M, and Taylor AJ: Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res. 1995;12:1682-1688.
89. Takanami C, and Goto Y: Physical properties of antibiotic aerosols produced by jet and ultrasonic nebulizers. J Aerosol Med. 1990;3:45-52.
90. Dennis JH: Drug nebuliser design and performance: breath enhanced jet vs. constant output jet vs. ultrasonic. J Aerosol Med. 1995;8:277-280.
91. Braitman LE: Confidence intervals assess both clinical significance and statistical significance. Ann Intern Med. 1991;114:515-517.
92. Ries AL: Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD. 2005;2:105-110.
93. Grimbert D, Lubin O, de Monte M, Vecellio None L, Perrier M, Carré P, Lemarié E, Boissinot E, and Diot P: [Dyspnea and morphine aerosols in the palliative care of lung cancer]. Rev Mal Respir. 2004;21(6 Pt 1):1091-1097.